That does prove you are probably correct. However I am curious why they wouldn't file. I don't entirely buy the theory that it could skew 1st line or 2nd line trials.
Although the study in question showed a statsig benefit in both PFS and OS for Tarceva vs placebo following first-line platinum chemo, panel members were unimpressed by the clinical significance of these improvements. LLY’s Alimta is approved in this maintenance setting.
Market Data 
Markets 
AI
